Antibody-drug conjugates (ADCs) are advancing cancer treatment, but their success depends on early safety insights and informed toxicology strategies. Xiaoxiao Wang, Yan Zhang, Junli Zhao, WuXi AppTec explains.
Shutterstock - agustin.photo
Strategic toxicology endpoints in ADC development
Antibody-drug conjugates (ADCs) are advancing cancer treatment, but their success depends on early safety insights and informed toxicology strategies. Xiaoxiao Wang, Yan Zhang, Junli Zhao, WuXi AppTec explains.
Published:
|
5 min read
Last updated:
Sign up to our newsletter
The week's biggest stories from this industry, direct to your inbox.